Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis
This cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk for progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.
Authors
- Mariet C.W. Feltkamp (ORCID: https://orcid.org/0000-0001-5993-9846)
- Bernard M.J. Uitdehaag (ORCID: https://orcid.org/0000-0002-9226-7364)
- Liza M. Y. Gelissen (ORCID: https://orcid.org/0009-0004-4864-1429)
- Eva M. M. Strijbis (ORCID: https://orcid.org/0000-0001-6705-5864)
- Zoé L. E. van Kempen (ORCID: https://orcid.org/0000-0001-9557-5381)
- Theo Rispens (ORCID: https://orcid.org/0000-0001-9600-1312)
- Bob W. van Oosten (ORCID: https://orcid.org/0000-0003-4536-6201)
- Brigit A. de Jong (ORCID: https://orcid.org/0000-0002-7005-7008)
- Joep Killestein (ORCID: https://orcid.org/0000-0002-6347-5957)
- Martijn T. Wijburg (ORCID: https://orcid.org/0000-0002-0490-5638)
Institutions
- Leiden University Medical Center (NL)
- Sanquin (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- JAMA Neurology
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1001/jamaneurol.2025.0337
- Citations
- 8
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 8.36